Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study

Drugs. 1987:33 Suppl 3:247-52. doi: 10.2165/00003495-198700333-00046.

Abstract

86 patients with a first myocardial infarction presenting within 6 hours of the onset of symptoms were randomly allocated to treatment with intravenous streptokinase or anisoylated plasminogen streptokinase activator complex (APSAC). Plasma concentrations of fibrinogen, plasminogen, alpha 2-antiplasmin and fibrinogen degradation products and thrombin and prothrombin times, were measured before the injection of the thrombolytic drug and every 3 hours during the first 24 hours. APSAC and streptokinase produced identical and important systemic effects. APSAC produced a slightly smaller decrease in fibrinogen concentrations. The duration of this systemic activity was about the same for the 2 drugs (congruent to 24 hours).

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Anistreplase
  • Fibrinogen / metabolism
  • Fibrinolysis / drug effects*
  • Fibrinolytic Agents / therapeutic use*
  • Humans
  • Myocardial Infarction / blood
  • Myocardial Infarction / drug therapy*
  • Plasminogen / metabolism
  • Plasminogen / therapeutic use*
  • Prothrombin Time
  • Streptokinase / therapeutic use*
  • Thrombin Time
  • alpha-2-Antiplasmin / metabolism

Substances

  • Fibrinolytic Agents
  • alpha-2-Antiplasmin
  • Anistreplase
  • Fibrinogen
  • Plasminogen
  • Streptokinase